Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel B Costa

Showing results (131-140 of 175) with videos related to

Pageof 18
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2013
Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancerErik Folch, Norihiro Yamaguchi, Paul A VanderLaan, et al.
Oncotarget|March 20, 2016
Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growthZsuzsanna Nemeth, Eva Csizmadia, Lisa Vikstrom, et al.
Lung Cancer (Amsterdam, Netherlands)|September 8, 2022
Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancerDaniel Sentana-Lledo, Hollis Viray, Andrew J Piper-Vallillo, et al.
Oncotarget|October 31, 2015
In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancerToshiyuki Hirano, Hiroyuki Yasuda, Tetsuo Tani, et al.
Nature Metabolism|September 20, 2019
miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinomaWen Cai Zhang, Julie M Wells, Kin-Hoe Chow, et al.
Lung Cancer (Amsterdam, Netherlands)|August 13, 2013
Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practiceNorihiro Yamaguchi, Paul A Vanderlaan, Erik Folch, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 1, 2010
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutationsWee-Lee Yeo, Gregory J Riely, Beow Y Yeap, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancersAntonio R Lucena-Araujo, Jason P Moran, Paul A VanderLaan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2016
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II TrialMasahiko Yanagita, Amanda J Redig, Cloud P Paweletz, et al.
Journal of Clinical Pathology|March 13, 2025
Patterns of HER2 expression and genomic correlates in lung cancer, with a focus on preanalytical variables impacting immunohistochemical staining resultsCristiana M Pineda, Lauren O'Loughlin, Heather L Benjamin, et al.
Pageof 18

Showing results (131-140 of 175) with videos related to

Sort By:
Pageof 18
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 17, 2013
Adequacy of lymph node transbronchial needle aspirates using convex probe endobronchial ultrasound for multiple tumor genotyping techniques in non-small-cell lung cancerErik Folch, Norihiro Yamaguchi, Paul A VanderLaan, et al.
Oncotarget|March 20, 2016
Alterations of tumor microenvironment by carbon monoxide impedes lung cancer growthZsuzsanna Nemeth, Eva Csizmadia, Lisa Vikstrom, et al.
Lung Cancer (Amsterdam, Netherlands)|September 8, 2022
Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancerDaniel Sentana-Lledo, Hollis Viray, Andrew J Piper-Vallillo, et al.
Oncotarget|October 31, 2015
In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancerToshiyuki Hirano, Hiroyuki Yasuda, Tetsuo Tani, et al.
Nature Metabolism|September 20, 2019
miR-147b-mediated TCA cycle dysfunction and pseudohypoxia initiate drug tolerance to EGFR inhibitors in lung adenocarcinomaWen Cai Zhang, Julie M Wells, Kin-Hoe Chow, et al.
Lung Cancer (Amsterdam, Netherlands)|August 13, 2013
Smoking status and self-reported race affect the frequency of clinically relevant oncogenic alterations in non-small-cell lung cancers at a United States-based academic medical practiceNorihiro Yamaguchi, Paul A Vanderlaan, Erik Folch, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 1, 2010
Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutationsWee-Lee Yeo, Gregory J Riely, Beow Y Yeap, et al.
Lung Cancer (Amsterdam, Netherlands)|August 28, 2016
De novo ALK kinase domain mutations are uncommon in kinase inhibitor-naïve ALK rearranged lung cancersAntonio R Lucena-Araujo, Jason P Moran, Paul A VanderLaan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 10, 2016
A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II TrialMasahiko Yanagita, Amanda J Redig, Cloud P Paweletz, et al.
Journal of Clinical Pathology|March 13, 2025
Patterns of HER2 expression and genomic correlates in lung cancer, with a focus on preanalytical variables impacting immunohistochemical staining resultsCristiana M Pineda, Lauren O'Loughlin, Heather L Benjamin, et al.
Pageof 18